Veregen Patent Expiration

Veregen is a drug owned by Ani Pharmaceuticals Inc. It is protected by 5 US drug patents filed from 2013 to 2019. Out of these, 2 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 02, 2026. Details of Veregen's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7858662 Medicament for the treatment of viral skin and tumour diseases
Oct, 2026

(1 year, 9 months from now)

Active
US9770406 Medicament for the treatment of viral skin and tumour diseases
Jul, 2025

(6 months from now)

Active
US10434059 Medicament for the treatment of viral skin and tumour diseases
Nov, 2022

(2 years ago)

Expired
US5795911 Composition for treating Condyloma acuminata
Oct, 2020

(4 years ago)

Expired
US5968973 Method for treating hyperplasia
Apr, 2017

(7 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Veregen's patents.

Given below is the list of recent legal activities going on the following patents of Veregen.

Activity Date Patent Number
Patent litigations
Expire Patent 13 Nov, 2023 US10434059
Maintenance Fee Reminder Mailed 29 May, 2023 US10434059
Expire Patent 30 Jan, 2023 US7858662
Maintenance Fee Reminder Mailed 15 Aug, 2022 US7858662
Surcharge for Late Payment, Large Entity 14 Jul, 2021 US9770406
Payment of Maintenance Fee, 4th Year, Large Entity 14 Jul, 2021 US9770406
Maintenance Fee Reminder Mailed 17 May, 2021 US9770406
Recordation of Patent Grant Mailed 08 Oct, 2019 US10434059
Patent Issue Date Used in PTA Calculation 08 Oct, 2019 US10434059
Email Notification 19 Sep, 2019 US10434059


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Veregen and ongoing litigations to help you estimate the early arrival of Veregen generic.

Veregen's Litigations

Veregen been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 08, 2015, against patent number US9770406. The petitioner , challenged the validity of this patent, with Yunik Chang et al as the respondent. Click below to track the latest information on how companies are challenging Veregen's patents.

Last updated on December 17, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9770406 September, 2015 Decision
(07 Feb, 2017)
Yunik Chang et al

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Veregen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Veregen's family patents as well as insights into ongoing legal events on those patents.

Veregen's Family Patents

Veregen has patent protection in a total of 21 countries. It's US patent count contributes only to 15.6% of its total global patent coverage. 14 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Veregen.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Veregen's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 02, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Veregen Generics:

There are no approved generic versions for Veregen as of now.

Alternative Brands for Veregen

Veregen which is used for treating genital warts., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Bausch
Zyclara Used for treating skin conditions caused by certain types of viruses.





About Veregen

Veregen is a drug owned by Ani Pharmaceuticals Inc. It is used for treating genital warts. Veregen uses Sinecatechins as an active ingredient. Veregen was launched by Ani Pharms in 2006.

Approval Date:

Veregen was approved by FDA for market use on 31 October, 2006.

Active Ingredient:

Veregen uses Sinecatechins as the active ingredient. Check out other Drugs and Companies using Sinecatechins ingredient

Treatment:

Veregen is used for treating genital warts.

Dosage:

Veregen is available in ointment form for topical use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
15% OINTMENT Prescription TOPICAL